The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Evaluating the role of fruquintinib in patients with refractory mCRC
Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses the impact of the approval of fruquintinib, a VEGF inhibitor, in patients with refractory metastatic colorectal cancer (mCRC). Findings from the FRESCO (NCT02314819) and FRESCO-2 (NCT04322539) trials, which assessed fruquintinib in patients from China and the rest of the world respectively. In the FRESCO-2 trial, patients who have progressed on trifluridine–tipiracil or regorafenib were recruited, and the primary endpoint of overall survival was met. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Elevar Therapeutics (Inst); Elevation Oncology; General Electric; GlaxoSmithKline; Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology; Merck (Inst); Merck Serono; natera; Pfizer; Pfizer (Inst); Seagen
